Gum health and mouth fluid markers in people with hepatitis B and D
Compares gum disease and mouth fluid markers in hepatitis B and D patients.
Plain-language title generated from the registry record
Registry title: Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
Key facts
- Where
- Craiova, RomaniaSee the 2 sites
Where in Romania
- Clinical Emergency County Hospital CraiovaCraiova, RomaniaTaking people
- University of Medicine and Pharmacy of CraiovaCraiova, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Research Center of Periodontal-Systemic Interactions
- Trial code
- NCT07491848
- Record updated
- 25 March 2026
- Original description
Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.Read full original descriptionShow less
Oral-Periodontal Evaluation and Assessment of Biomarkers in Oral Fluids in Patients With Hepatitis B+D Treated With Bulevirtide
Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.
Inclusion: Adults (≥18 years old) capable of providing informed consent; For Hepatitis B+D groups: confirmed hepatitis B and D co-infection; Bulevirtide group: receiving bulevirtide therapy as prescribed; No Bulevirtide group: not receiving bulevirtide; For Healthy Control group: systemically healthy adults without hepatitis B or D infection; Willingness to undergo oral-periodontal examination, saliva and gingival crevicular fluid collection, and oral cavity photography.
Exclusion: Patients currently receiving other experimental therapies that may affect oral or systemic inflammation; Patients with other systemic diseases that could influence periodontal health (e.g., uncontrolled diabetes, autoimmune diseases); History of oral or periodontal surgery within the last 6 months that could affect measurements; Pregnancy or lactation; Inability or unwillingness to provide informed consent.